What the Veradermics Phase 3 results mean for oral minoxidil treatment
Veradermics reports strong Phase 3 VDPHL01 hair growth results in 536 men. Efficacy is encouraging, but safety and FDA review remain crucial.
Pharma & Biotech
Pharma & Biotech
Pelage’s hair-loss drug showed a 31% early response rate. Can 600 patients confirm it?
Pelage has dosed the first participant in AWAKEN, a 600-patient Phase 2/3 trial of topical PP405 for male pattern hair loss. The programme follows an exploratory Phase 2a finding in which 31% of selected treated men achieved more than 20% improvement in hair density, compared with none receiving placebo.
Pharma & Biotech
Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data
See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.
Pharma & Biotech
Will Veradermics’ non-hormonal oral pill become the first FDA-approved hair loss therapy in decades?
Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.